Market opens lower on weak Asian cues

Image
Capital Market
Last Updated : Sep 04 2015 | 10:47 AM IST

Key benchmark indices edged lower in early trade tracking weakness in Asian markets. The barometer index, the S&P BSE Sensex was currently down 175.88 points or 0.68% at 25,588.90. The 50-unit CNX Nifty was currently off 52.60 points or 0.67% at 7,770.40. The market breadth indicating the overall health of the market was weak on BSE.

Among individual stocks, Lupin edged higher after the company's US subsidiary launched a generic antidepressant medicine in the United States.

Overseas cues were negative. Asian stocks were in red while US stocks ended on a mixed note yesterday, 3 September 2015.

At 9:19 IST, the S&P BSE Sensex was down 175.88 points or 0.68% at 25,588.90. The 50-unit CNX Nifty was off 52.60 points or 0.67% at 7,770.40.

The BSE Mid-Cap index was down 74.04 points or 0.7% at 10,486.17. The decline in the index was higher than Sensex's decline in percentage terms. The BSE Small-Cap index was down 62.70 points or 0.58% at 10,810.85. The decline in the index was lower than Sensex's decline in percentage terms.

The market breadth indicating the overall health of the market was weak. On BSE, 754 shares declined and 282 shares rose. A total of 37 shares were unchanged.

Lupin edged higher after the company's US subsidiary launched a generic antidepressant medicine in the United States. The stock rose 0.43% to Rs 1,871.15. Lupin's US subsidiary Lupin Pharmaceuticals, Inc. (Lupin) has launched a generic antidepressant medicine Duloxetine 40 mg Delayed-Release (DR) Capsule in the United States. Lupin's Duloxetine 40 mg delayed-release (DR) capsule is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength in the US. The annual market size of the branded and generic versions of antidepressant Cymbalta 20 mg, 30 mg and 60 mg capsule strengths is approximately $1.05 billion in the US, as per IMS MAT June 2015 data.

Among global events, at a key monetary policy meeting yesterday, 3 September 2015, the European Central Bank (ECB) cut its growth and inflation forecasts, warning of possible further trouble from China and paving the way for an expansion of its already massive one-trillion-euro-plus asset-buying program. The ECB, which left interest rates unchanged, said growth would suffer from fading momentum in emerging markets, particularly China, and falling oil prices could drag the 19-member euro zone back into deflation in coming months.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 04 2015 | 9:21 AM IST

Next Story